1
|
Bozinovic N, Aguiar VMD, Ferry A, Gallier F, Lubin-Germain N, Uziel J, Miranda LSDME. Studies on the synthesis of 1'-CN-triazolyl- C-ribosides. Org Biomol Chem 2022; 20:7261-7269. [PMID: 36069280 DOI: 10.1039/d2ob01403c] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The search for broad-spectrum antiviral compounds is a continuous mandatory effort. The recent approval of the first C-nucleoside carrying a nitrile as a substituent at the C1' position of the ribose ring has raised interest in this underexplored substitution pattern. We have previously reported the development of different 1,2,3-triazolyl-C-ribonucleosides with anticancer and antiviral activities. Herein we report our results on the incorporation of a C1'-CN group in 1,2,3-triazolyl-C-ribonucleosides.
Collapse
Affiliation(s)
- Nina Bozinovic
- CY Cergy Paris Université, CNRS, BioCIS, 95000, Cergy-Pontoise, France
| | - Viviane Marques de Aguiar
- Biocatalysis and Organic Synthesis Group, Universidade Federal do Rio de Janeiro, Av Athos da Silveira Ramos 149, Centro de Tecnologia, Bl A, 21941909 Ilha do Fundão, Rio de Janeiro, Brazil.
| | - Angélique Ferry
- CY Cergy Paris Université, CNRS, BioCIS, 95000, Cergy-Pontoise, France
| | - Florian Gallier
- CY Cergy Paris Université, CNRS, BioCIS, 95000, Cergy-Pontoise, France
| | | | - Jacques Uziel
- CY Cergy Paris Université, CNRS, BioCIS, 95000, Cergy-Pontoise, France
| | - Leandro Soter de Mariz E Miranda
- CY Cergy Paris Université, CNRS, BioCIS, 95000, Cergy-Pontoise, France.,Biocatalysis and Organic Synthesis Group, Universidade Federal do Rio de Janeiro, Av Athos da Silveira Ramos 149, Centro de Tecnologia, Bl A, 21941909 Ilha do Fundão, Rio de Janeiro, Brazil.
| |
Collapse
|
2
|
Gonzalez S, Brzuska G, Ouarti A, Gallier F, Solarte C, Ferry A, Uziel J, Krol E, Lubin-Germain N. Anti-HCV and Zika activities of ribavirin C-nucleosides analogues. Bioorg Med Chem 2022; 68:116858. [PMID: 35661850 DOI: 10.1016/j.bmc.2022.116858] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2022] [Revised: 05/23/2022] [Accepted: 05/25/2022] [Indexed: 11/27/2022]
Abstract
Ribavirin is an unnatural nucleoside exhibiting broad spectrum of antiviral and antitumor activities, still very widely studied particularly in a repositioning approach. C-triazolyl nucleoside analogues of ribavirin have been synthesized, as well as prodrugs and glycosylated or peptide conjugates to allow a better activity by vectorization into the liver or by facilitating uptake into the cells. The antiviral properties of all synthesized compounds have been evaluated in vitro against two important human viral pathogens belonging to the Flaviviridae family: hepatitis C virus (HCV) and Zika virus (ZIKV). There are no therapeutic options for Zika virus, whereas those available for HCV can be still improved. Our results indicated that compound 2 carrying an N-hydroxy carboxamide function exhibits the most inhibitory activities against both viruses. This compound moderately inhibited the propagation of HCV with an IC50 value of 49.1 μM and Zika virus with an IC50 of 33.2 μM comparable to ribavirin in the Vero cell line. The results suggest that compound 2 and its new derivatives may be candidates for further development of new anti-HCV and anti-ZIKV antiviral drugs.
Collapse
Affiliation(s)
- Simon Gonzalez
- CY Cergy Paris Université, CNRS, BioCIS, 95000 Cergy Pontoise, France; Université Paris-Saclay, CNRS, BioCIS, 92290 Châtenay-Malabry, France
| | - Gabriela Brzuska
- Department of Recombinant Vaccines, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Abrahama 58, 80-307 Gdansk, Poland
| | - Abdelhakim Ouarti
- CY Cergy Paris Université, CNRS, BioCIS, 95000 Cergy Pontoise, France; Université Paris-Saclay, CNRS, BioCIS, 92290 Châtenay-Malabry, France
| | - Florian Gallier
- CY Cergy Paris Université, CNRS, BioCIS, 95000 Cergy Pontoise, France; Université Paris-Saclay, CNRS, BioCIS, 92290 Châtenay-Malabry, France
| | - Carmen Solarte
- CY Cergy Paris Université, CNRS, BioCIS, 95000 Cergy Pontoise, France; Université Paris-Saclay, CNRS, BioCIS, 92290 Châtenay-Malabry, France
| | - Angélique Ferry
- CY Cergy Paris Université, CNRS, BioCIS, 95000 Cergy Pontoise, France; Université Paris-Saclay, CNRS, BioCIS, 92290 Châtenay-Malabry, France
| | - Jacques Uziel
- CY Cergy Paris Université, CNRS, BioCIS, 95000 Cergy Pontoise, France; Université Paris-Saclay, CNRS, BioCIS, 92290 Châtenay-Malabry, France
| | - Ewelina Krol
- Department of Recombinant Vaccines, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Abrahama 58, 80-307 Gdansk, Poland.
| | - Nadège Lubin-Germain
- CY Cergy Paris Université, CNRS, BioCIS, 95000 Cergy Pontoise, France; Université Paris-Saclay, CNRS, BioCIS, 92290 Châtenay-Malabry, France.
| |
Collapse
|